218 related articles for article (PubMed ID: 8126248)
41. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
42. Erythropoietin and renal transplantation.
Muirhead N
Kidney Int Suppl; 1999 Mar; 69():S86-92. PubMed ID: 10084292
[TBL] [Abstract][Full Text] [Related]
43. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
44. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients.
Tarng DC; Chen TW; Huang TP
Am J Nephrol; 1995; 15(3):230-7. PubMed ID: 7618648
[TBL] [Abstract][Full Text] [Related]
45. Iron status in patients receiving erythropoietin for dialysis-associated anemia.
Van Wyck DB; Stivelman JC; Ruiz J; Kirlin LF; Katz MA; Ogden DA
Kidney Int; 1989 Feb; 35(2):712-6. PubMed ID: 2709674
[TBL] [Abstract][Full Text] [Related]
46. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
47. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
49. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
[TBL] [Abstract][Full Text] [Related]
50. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
51. Erythropoietin and iron: the role of ascorbic acid.
Tarng DC; Huang TP; Wei YH
Nephrol Dial Transplant; 2001; 16 Suppl 5():35-9. PubMed ID: 11509682
[TBL] [Abstract][Full Text] [Related]
52. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
53. [Treatment of anemia with erythropoietin (rhuEPO) in patients with chronic kidney failure who are not yet in need of dialysis therapy].
Wiecek A; Kokot F; Marcinkowski W; Rudka R; Klimek D
Pol Arch Med Wewn; 1992 Nov; 88(5):310-23. PubMed ID: 1300551
[TBL] [Abstract][Full Text] [Related]
54. [Treatment of anemia in chronically dialyzed patients].
Moynot A
Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
[No Abstract] [Full Text] [Related]
55. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
[TBL] [Abstract][Full Text] [Related]
56. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
57. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia.
Müller R; Steffen HM; Brunner R; Saric J; Pollok M; Baldamus CA; Kaufmann W
Clin Invest Med; 1991 Dec; 14(6):614-22. PubMed ID: 1665406
[TBL] [Abstract][Full Text] [Related]
58. How and when to use erythropoietin.
Cazzola M
Curr Opin Hematol; 1998 Mar; 5(2):103-8. PubMed ID: 9570702
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of adjuvant recombinant human erythropoietin and ferrous sulfate as treatment for iron deficiency anemia during the third trimester of pregnancy.
Sanchez-Gonzalez LR; Castro-Melendez SE; Angeles-Torres AC; Castro-Cortina N; Escobar-Valencia A; Quiroga-Garza A
Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():32-6. PubMed ID: 27566219
[TBL] [Abstract][Full Text] [Related]
60. Iron supplementation in renal anemia.
Fishbane S
Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
